Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis
<p><strong>Background</strong> Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation. In the phase 3 study (NCT02414854), add-on dupilumab 200 mg/300 mg every 2 weeks, versus placebo, sign...
Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Elsevier
2019
|